Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

NCT01656889
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP-802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

NCT04331080
View directory record Official record
Conditions
Mammoplasty, Scarring, Scar, Breast Reconstruction
Interventions
Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Pasadena, California • Doral, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 2 Interventional

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

NCT00941486
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100 Ophthalmic Suspension, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

NCT04362670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OTX-CSI, Placebo Vehicle
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Ivermectin 1% Cream

NCT02840461
View directory record Official record
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
Ivermectin Cream, 1%, Placebo/Vehicle cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

NCT01959243
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

NCT07546214
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ALC-919 For The Treatment Of Common Warts

NCT02483455
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
2014-ALC-919-US, Vehicle-Control Topical Solution
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Washington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Vehicle cream
Drug · Other
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 3, 2026, 7:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
Other · Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
14
States / cities
Aliso Viejo, California • Garden Grove, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

Study of TDM-180935 in Atopic Dermatitis Patients

NCT06363461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974323
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beverly Hills, California • Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

NCT01290367
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Single Dose MPCs Injection, Single injection of saline solution, Single injection of hyaluronic acid
Biological · Procedure
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
View directory record Official record
Conditions
Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy
Drug · Radiation
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

NCT01706679
View directory record Official record
Conditions
Healthy
Interventions
ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg), Placebo vehicle (PBS)
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 3, 2026, 7:08 PM EDT